Clinical Trials Logo

Portopulmonary Hypertension clinical trials

View clinical trials related to Portopulmonary Hypertension.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03309592 Withdrawn - Clinical trials for Pulmonary Hypertension

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

Start date: October 12, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of the combination of ambrisentan and tadalafil in reducing mPAP to below 35mmHg in patients with moderate to severe Portopulmonary Hypertension (POPH) as a means to candidacy for liver transplantation.

NCT ID: NCT01733095 Withdrawn - Clinical trials for Portopulmonary Hypertension

Ambrisentan for Treatment of Portopulmonary Hypertension

Start date: July 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension and is present in approximately 5% of cirrhotic patients. Treatment options include prostanoids, sildenafil, and the endothelin-receptor antagonists, bosentan and ambrisentan. This study investigates the safety and efficacy of ambrisentan in portopulmonary hypertension.